Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Britain Courts Anthropic Amid US Defense Department Dispute 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
EAST RUTHERFORD, N.J., Sept. 06, 2016 -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a SEK 72 million ($9 million) investment to expand large scale manufacturing capacity at its Karlskoga facility in Sweden.
The investment includes the installation of new multi-purpose reactors ranging from 4m3 to 12m3 and upgrading of the control room within an existing plant on site. The new facilities will undergo validation and cGMP qualification ahead of the operational startup in Q4 2016. This extra capacity increases the large scale manufacturing capabilities of the Karlskoga facility, which supports clients’ development projects from R&D through to large scale commercial manufacturing.
“Our facility at Karlskoga is strategically important, both in Scandinavia and the wider European markets, and this investment is in response to an increase in demand for larger scale, multi-purpose manufacturing capabilities,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga. “By creating greater capacity within the current infrastructure, we have combined expansion and efficiency at the site, both of which will benefit our customers.”
The expansion at Cambrex’s Swedish site is part of an ongoing strategic campaign to invest in small molecule API manufacturing across its global network of facilities.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Alex Maw Director, Marketing and Communications Phone: +44 7803 443 155 Email: [email protected]
